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1078–5884/00The Impact of Immunological Parameters on the
Development of Phantom Pain after Major Amputation
C. Stremmel,1*, C. Horn,1, S. Eder,1 A. Dimmler2 and W. Lang11Section of Vascular Surgery, Department of Surgery, Friedrich Alexander Universita¨t Erlangen-Nu¨rnberg,
and 2Institute of Pathology, University of Erlangen-Nu¨rnberg, Erlangen, GermanyObjectives. To investigate the relationship between local and systemic inflammatory markers and phantom limb pain.
Methods. In 39 consecutive patients undergoing major amputations nerve biopsies, serum and clinical data was collected.
Patients were followed up for 12 months to report on the incidence and severity of phantom limb pain.
Results. After 12 months, 78% of the surviving patients had phantom pain, the symptom usually commencing within 14
days of operation. The severity of macrophage infiltration within the nerve biopsy was negatively correlated to the inception
of phantom pain (PZ0.026). While serum TNF-alpha concentration was positively correlated to mortality (PZ0.021).
Conclusions. The immune status existing before the amputation and the local immunological milieu influence the onset of
phantom pain.Keywords: Phantom pain; Immunological parameters; Prognostic factors; Human nerve tissue.Phantom pains are neuropathic pain that may occur
after amputation of limbs and which are referred to the
missing limb or the missing organ.1–5 An extremely
wide range of clinical parameters have been claimed to
be associated with phantom pain. However, despite
numerous studies encompassing various clinical
parameters, none of these factors has actually been
shown to have any correlation with the occurrence of
phantom pain, either in randomised or in independent
studies.1 The exact pathogenesis of phantom pain is
still unclear, this being one of the main reasons why
successful therapy has not yet been discovered.6,7
Experiments in numerous animal models have shown
that the immunological component plays an important
role in the occurrence of pain.8–10 The purpose of this
study was to examine the impact of immunological
parameters on the prognosis and pathogenesis of
phantom pain.ing author. Dr Christian Stremmel, Thoracic Surgery
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0079 + 04 $35.00/0 q 2005 Elsevier Ltd. All rights reserMaterials and MethodsPatients
This study comprised 39 consecutive patients who
were treated by a major amputation of the lower limb
performed in the Department of Vascular Surgery of
the University of Erlangen-Nu¨rnberg during the
period from July 2000 to July 2001. Clinical data
were recorded prospectively for all these patients,
including a pain questionnaire adapted from Kooij-
man et al.11 Clinical data were recorded preoperatively,
on the day of discharge, and thereafter every 3 months
until the end of follow-up. In addition, nerve tissue
was taken from each patient during the operation,
snapped-frozen in liquid nitrogen and stored at
K80 8C for subsequent processing.Immunocytochemistry and quantification
We used the following primary antibodies for
immunocytochemistry (anti-human CD3, clone-
NCLCD3p), anti-human CD4 (clone-NCL-CD4-1F6),
anti-human CD8 (clone-C8/1440), CD20 (clone-L26),
CD68 (clone-PG-M1), TNF-alpha (clone-28401.111),
TNF-RI (R&D Systems) and HOI (clone-N19) was
applied at appropriate dilution (100–200 ml/slide).Eur J Vasc Endovasc Surg 30, 79–82 (2005)
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Table 1. Association between immune cells and cytokines in nerves and the occurrence of phantom pain
Phantom pain postoperative P value
Yes (SD) No (SD)
CD3 13 (15.7) 15 (19.4) 0.744
CD20 2 (6.5) 2 (3.1) 0.893
CD68 2 (4) 5 (3.3) 0.026
TNF-a 3 (8.4) 3 (5.5) 0.973
TNF-a-RI 16 (45.9) 13 (23.2) 0.973
HOI 8 (13.5) 16 (33.1) 0.328
Each line shows the median number of positive staining cells for each marker, counted in three microscope fields at 20!magnification; TNF-
a-RI, tumor necrosis factor-alpha-receptor I; HOI, hemeoxygenase1; SD, standard deviation.
C. Stremmel et al.80Slides were viewed with a 40! objective and an area
of the nerve was chosen that was free of artefacts. All
immunoreactive cells were counted within a defined
field measuring 240!180 mm2. Three such fields were
analysed.ELISA
Serum was collected from 32 patients on admission to
hospital. ELISAs were performed for TNF-alpha,
sICAM-1, interleukin-6 (R&D System) and C-reactive
protein (C-reactive Protein, Olympus System, Olym-
pus Diagnostica).Fig. 1. This diagram shows the distribution of macrophages
(CD68) in the axon in a patients with (above) and without
(below) phantom pain, as revealed with the aid of
immunohistochemistry. The images are reproduced at 20!
magnification.
Eur J Vasc Endovasc Surg Vol 30, July 2005Statistics
The clinical data together with the experimental data
derived from the immunohistochemical studies and
the serum assays were analyzed using SPSS (SPSS for
Windows 11.0) databank. The significance level was
taken as P!0.05.ResultsPatients and frequency of phantom pain
A total of 39 patients was enrolled in the study.
Twenty-one patients (54%) developed phantom pain
within the first 14 days after the operation. From
discharge up to the end of follow-up six further
patients developed phantom pain. Patients who had
no phantom pain at the end of 6 months did not
develop any phantom pain up to the end of follow-up
at 12 months.Correlation between routine preoperative laboratory
parameters and the occurrence of phantom pain
The routine preoperative laboratory investigations
comprised full blood count, clotting parameters,
LDL, HDL, Quick, PTT and creatinine, were not
correlated with the occurrence of phantom pain.Correlation between immunological parameters and
phantom pain
Soluble ICAM, C-reactive protein (CrP), interleukin-6,
TNF-alpha, TNF-a-RI and HIO were of no value for
predicting phantom pain (data not shown). Immune
cells were demonstrable in almost every nerve biopsy
removed at the time of amputation. T-cells (CD3C)
were most frequently identified, with smaller number
of B-cells (CD20) and macrophages (CD68) also seen.
Macrophages were less frequently identified in the
Table 2. Clinical and immunological parameters as prognostic factors for survival 12 months after amputation
Survival after 12 months P value
Alive Dead
N 27 12
CrP (mg/l) 96 (85.9) 61 (62.5) 0.823
sICAM (ng/ml) 21.5 (10.2) 26 (11.5) 0.110
Interleukin-6 (pg/ml) 33.5 (13) 33 (12.4) 0.350
TNF-a (pg/ml) 4 (1.8) 8 (2.6) 0.021
Phantom pain at discharge 14 7 0.742
Quick (%) 75 67 0.147
Diabetes mellitus 21 7 0.173
Hypertension 21 9 0.832
HDL (mg/dl) 30.5 (10.1) 35 (11.2) 0.561
LDL (mg/dl) 75.5 (23.5) 122 (45) 0.380
For each parameter the median is shown. SD, standard deviation.
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developed phantom pain (PZ0.026) (Table 1) (Fig. 1).Prognostic markers for survival after a major amputation
In the first 3 months after amputation 20% of the
patients died. At the end of follow-up after 12 months,
only 27 (67%) of the patients who had had a major
amputation were still alive. Because of the high
mortality of 33% at 12 months, we examined various
clinical and immunological parameters to assess their
value for predicting survival. Other concomitant
diseases were of no relevance for 1-year survival.
Surviving patients had serum levels of TNF-alpha
which were about 50% lower (PZ0.021, Mann–
Whitney U test). sICAM, interleukin-6 and CrP
showed no association with survival. The occurrence
of phantom pain did not correlate with survival (Table
2).Discussion
Patients who have to undergo a major amputation
have increased morbidity and mortality after the
operation. The principal morbidity is phantom pain,
which has a prevalence of up to 78%.1,2 In our series,
phantom pain usually began within the first 14 days.
Data from animal experiments suggest that immuno-
logical regulatory circuits are of critical importance for
the inception of chronic pain.8–10 As phantom pain is a
chronic pain phenomenon beginning immediately
after the amputation,1 it seems reasonable to suppose
that immune reactions within nerves, initiated even
before the amputation, might influence the disease
process.
In nerves from phantom pain patients, fewer
macrophages (CD68C cells) were demonstrable than
in nerves from patients who did not develop anyphantom pain. Numerous studies in experimental
animals have shown that macrophages, play a central
role in the induction of chronic pain.9,10 In our
investigations of human tissues the appearance of
macrophages had a protective effect against the onset
of phantom pain. Conceivably, by the production of
antioxidants such as glutathione, macrophages may
help to protect nerves against free radicals through the
production of antioxidants such as glutathione.9,10
In this study, we also identified an association
between serum TNF-alpha concentrations at the time
of operation and subsequent survival. This association
likely reflects this cytokine as a marker of athero-
sclerosis burden or associated co-morbidities.12,13
Our data suggests an influence of local inflam-
mation on the development of phantom pain. Further
studies are required to clarify the mechanisms that
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